ARTICLE | Clinical News
China approves Solasia's oral mucositis product
February 22, 2019 5:15 PM UTC
Solasia Pharma K.K. (Tokyo:4597) said China's National Medical Products Administration approved Episil (SP-03) to relieve pain associated with oral mucositis. The company added ¥50 (31%) to ¥210 on Feb. 21.
Episil is a lipid-based liquid that adheres to the oral mucosa and forms a protective FluidCrystal film. The product is also approved in the U.S., Europe and Japan...